scholarly journals Long-Term Outcomes of Pediatric Enterovirus Infection in Taiwan: A Population-Based Cohort Study

2020 ◽  
Vol 8 ◽  
Author(s):  
Jui-Ju Tseng ◽  
Chien-Heng Lin ◽  
Ming-Chih Lin
Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4968-4968
Author(s):  
Adi J. Klil-Drori ◽  
Sara Nazha ◽  
Marlene Gharib ◽  
Sylvie Perreault ◽  
Vicky Tagalakis

Background: Enoxaparin given once daily (QD) for thrombotic disorders is less burdensome than twice-daily (BID) dosing. However, long-term outcomes when enoxaparin given as QD monotherapy are unknown. Methods: We did a population-based cohort study. New users of enoxaparin alone (2005-2014) were identified in the linked healthcare databases of Quebec, Canada, and followed up for up to one year. The number of dispensed syringes divided by prescription length determined QD or BID enoxaparin by intention to treat. Cumulative rates of major bleeding and re-treatment with anticoagulants at one year were compared between enoxaparin groups. Re-treatment was initiation of anticoagulation after at least 30 days of no dispensed anticoagulants. The duration of enoxaparin monotherapy was the sum of prescriptions until discontinuation. Results: The cohort included 504 patients; QD and BID enoxaparin users were 445 and 59, respectively. Mean (SD) age was 78.0 (6.6) years, 43.8% were males, and 61.9% had cancer. At 12 months, major bleeding occurred in 21 (4.7%) and 4 (6.8%) among QD and BID enoxaparin users, respectively (Figure 1A, P = 0.49). Re-treatment with anticoagulants occurred in 37 (9.6%) and 5 (9.4%) of QD and BID users, respectively (Figure 1B, P = 0.98). The duration of enoxaparin monotherapy was on average 13.9 (95% CI, 4.4-23.4, P = 0.005) days longer with QD vs BID use. Conclusions: Monotherapy with QD enoxaparin was common and longer than BID enoxaparin with no apparent differences in bleeding or re-treatment with anticoagulants. Figure 1 Disclosures Klil-Drori: Sanofi Canada: Research Funding. Nazha:Sanofi Canada: Employment. Gharib:Sanofi Canada: Employment. Perreault:Sanofi Canada: Research Funding. Tagalakis:Servier: Other: participated on ad boards; Bayer: Other: participated on ad boards; Pfizer: Other: participated on ad boards; Sanofi Aventis: Other: investigator initiated grant;participated on ad boards; BMS-Pfizer: Other: participated on ad boards.


Kidney360 ◽  
2020 ◽  
Vol 1 (7) ◽  
pp. 640-647 ◽  
Author(s):  
Allison C. Ouellette ◽  
Elizabeth K. Darling ◽  
Branavan Sivapathasundaram ◽  
Glenda Babe ◽  
Richard Perez ◽  
...  

BackgroundThere are limited data at a population level on the burden, risk factors, and long-term outcomes of neonatal renal vein thrombosis (nRVT). We conducted a population-based cohort study to understand the epidemiology and outcomes of nRVT over a 25-year period in Ontario.MethodsUsing linked administrative health databases, all hospitalized neonates ≤28 days born in Ontario between 1992 and 2016 with nRVT were identified. The primary outcome was to calculate the incidence of nRVT and trend over time in Ontario. We also determined the risk factors associated with nRVT as well as the risk of long-term outcomes after nRVT, including CKD, ESKD, all-cause mortality, and hypertension (HTN) compared with the healthy neonatal population without nRVT.ResultsThe annual incidence rate of nRVT was 2.6 per 100,000 live births (n=85). Presence of respiratory distress syndrome (OR, 8.01; 95% CI, 4.90 to 13.1), congenital heart disease (OR, 9.1; 95% CI, 5.05 to 16.4), central venous catheterization (OR, 3.9; 95% CI, 1.89 to 7.93), maternal preeclampsia (OR, 2.8; 95% CI, 1.6 to 4.79), and maternal diabetes (OR, 2.36; 95% CI, 1.36 to 4.07) conferred the highest risk for nRVT. Over a median follow-up of 15 years and after adjusting for confounders, neonates with nRVT versus the comparator cohort had a 15.5-fold risk of CKD, HTN, or death (n=49 [58%] versus n=90,050 [3%]; 95% CI, 11.7 to 20.6); 12.3-fold increased risk of CKD or death (n=39 [46%] versus n=32,016 [1%]; 95% CI, 8.9 to 16.8); and a 15.7-fold increased risk of HTN (n=33 [39%] versus n=64,458 [2%]; 95% CI, 11.1 to 21.1). None of the nRVT cohort developed ESKD. The median time to composite outcome of CKD, HTN, or death was 11.1 years.ConclusionsPatients with a history of nRVT remain at higher risk than the general population for long-term morbidity or mortality, indicating the need for long-term follow-up.


2015 ◽  
Vol 2 (6) ◽  
pp. 532-539 ◽  
Author(s):  
Yaron Finkelstein ◽  
Erin M Macdonald ◽  
Simon Hollands ◽  
Janine R Hutson ◽  
Marco L A Sivilotti ◽  
...  

BMJ ◽  
2015 ◽  
pp. h3557 ◽  
Author(s):  
Olivier Aubert ◽  
Nassim Kamar ◽  
Dewi Vernerey ◽  
Denis Viglietti ◽  
Frank Martinez ◽  
...  

2017 ◽  
Vol 69 (1) ◽  
pp. 18-28 ◽  
Author(s):  
Simon Sawhney ◽  
Angharad Marks ◽  
Nick Fluck ◽  
Adeera Levin ◽  
Gordon Prescott ◽  
...  

2014 ◽  
Vol 45 (2) ◽  
pp. 188-194 ◽  
Author(s):  
Chu-lin Chou ◽  
Tsung-cheng Hsieh ◽  
Chih-hsien Wang ◽  
Tsung-hsing Hung ◽  
Yu-hsien Lai ◽  
...  

Author(s):  
Ralph K. Akyea ◽  
Wolfram Doehner ◽  
Barbara Iyen ◽  
Stephen F. Weng ◽  
Nadeem Qureshi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document